Commercialization of Advanced Technologies That Will Change the Way Transplantation Medicine is Practiced Today
Early detection of transplant rejection or disease relapse is critical for the adjustment of a transplant recipient’s treatment regime, graft survival and higher quality of life for patients. JETA’s products provide best in class solutions for post-transplant monitoring of transplant rejection and disease relapse
Pre-arrayed typing trays allow for easy testing setup - simply dispense master mix containing DNA to the plate, then thermal cycle. With 46 INDEL assays, the QTRACE® Analysis System offers the highest resolution against any competing qPCR-based Chimerism tests available.
QTRACE® INDEL Monitoring Assays, QTRACE® RNaseP Reference Gene Assay and QTRACE® qPCR Master Mix provide precise and accurate quantification of minor component DNA after stem cell transplantation.
QTRACE® Software provides the most customizable qPCR chimerism software currently on the market. QTRACE® Software generates protocols, analyzes data, identifies informative loci, generates reports, provides longitudinal sample tracking and easy LIMS integration with many user-defined Preferences available.
About JETA Molecular
JETA Molecular is a molecular diagnostics company focused on commercialization of advanced technologies that will change the way transplantation medicine is practiced today. Early detection of transplant rejection or disease relapse is critical for the adjustment of a transplant recipient’s treatment regime, graft survival and higher quality of life for patients. JETA’s tests will provide best in class solutions for post-transplant monitoring of transplant rejection and disease relapse. JETA’s solutions will enable new applications and will translate into better patient care and survival rates.
JETA’s founders have extensive expertise in the design, development and commercialization of IVD/CE-marked, ASR/GPR and RUO molecular diagnostic kits and software for transplantation and human genetic testing. JETA has support from, and collaborations with, key opinion leaders in the fields of stem cell and solid organ transplantation. It is through these relationships that clinical utility of JETA’s approaches has been established.